Oxfam is closely watching the outcome of Novartis’ endless and highly
damaging challenge to Section 3(d) of India’s Patent Act. We are profoundly disappointed that Novartis has continued to pursue legal action against the Indian Government. Five years ago, hundreds of thousands of people called upon Novartis to drop its legal challenge against the Indian. Today, over 2 billion people still lack regular access to affordable medicines, and yet Novartis has persisted. Oxfam is seriously concerned that if Novartis succeeds, it will lead to long term and profound changes in India’s patent system that will undermine generic competition and access to affordable,low-cost medicines.
- RCEP negotiators must fix the damaging provisions that remain a threat to public health
- Escaping Big Pharma’s Pricing With Patent-Free Drugs
- An Access Regime based on Indian Patents Act -Review Of “The Access Regime” by Feroz Ali
- COLD RECEPTION TO RCEP AS PEOPLE’S RESISTANCE CONSOLIDATES
- Company sues Ukraine in bid to corner hepatitis C drug market